Interview of patients with HR+/HER2- metastatic breast cancer who received capivasertib + fulvestrant

Trial Identifier:	D3615R00004
Sponsor:	AstraZeneca
Start Date:	July 2025
Primary Completion Date:	December 2025
Study Completion Date:	December 2025
Condition:	Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
USA, California	Redwood Shores, California, USA, 94065

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.